3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
2
Ovarian Neoplasms
2
Myelodysplastic Syndromes
2
Leukemia, Myeloid, Acute
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Myeloproliferative Disorders
1
Myeloid Malignancy
1
MDS
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Rituximab
93
Cyclophosphamide
72
fludarabine phosphate
53
Whole-Body Irradiation
43
Mycophenolic Acid
40
Peripheral Blood Stem Cell Transplantation
39
Bortezomib
30
Tacrolimus
29
Etoposide
29
Cyclosporine
28
Melphalan
26
Filgrastim
26
Busulfan
26
Methotrexate
24
Lenalidomide
23
Cytarabine
23
ibrutinib
20
Vincristine
20
Granulocyte Colony-Stimulating Factor
20
Antilymphocyte Serum
20
Doxorubicin
18
Bendamustine Hydrochloride
18
Dexamethasone
16
Sirolimus
14
fludarabine
13
Carmustine
13
Cord Blood Stem Cell Transplantation
12
Calcium Dobesilate
12
Radiotherapy
11
Prednisone
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma, Mantle-Cell
×
eprenetapopt
×
Clear all
NCT04419389
2025-03-17
R/R
Aprea Therapeutics
Phase 1/2
Terminated
1 enrolled
4 charts